Follicular thyroid cancer medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{Ammu}} | {{CMG}}; {{AE}} {{Ammu}} | ||
==Overview== | ==Overview== | ||
Patients with follicular thyroid cancer are treated with radioactive iodine therapy and | Patients with follicular thyroid cancer are treated with radioactive iodine therapy and targeted medical therapy. | ||
==Medical Therapy== | ==Medical Therapy== | ||
Revision as of 15:07, 2 November 2015
|
Follicular thyroid cancer Microchapters |
|
Differentiating Follicular thyroid cancer from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Follicular thyroid cancer medical therapy On the Web |
|
American Roentgen Ray Society Images of Follicular thyroid cancer medical therapy |
|
Risk calculators and risk factors for Follicular thyroid cancer medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Patients with follicular thyroid cancer are treated with radioactive iodine therapy and targeted medical therapy.
Medical Therapy
Thyroid Hormone Replacement
- Thyroxine is recommended as a replacement therapy for all patients with follicular thyroid cancer especially for micronodular pulmonary metastases.[1]
Radioactive Iodine Therapy
- Radio active iodine ablation therapy may be used to prevent the recurrence of cancer.
- High doses of radioiodine is also used to treat microscopic bone metastasis
Targeted Therapy
Kinase Inhibitors
- Sorafenib
- Lenvatinib
Radiation Therapy
- External radiation therapy is used for bone pain in bone metastasis.
Other Treatment Options
- Intravenous infusions of bisphosphonate is also used to reduce pain in bone metastasis.
- Corticosteroid therapy is recommended for cerebral edema secondary to brain metastasis.
Reference
- ↑ McHenry, C. R.; Phitayakorn, R. (2011). "Follicular Adenoma and Carcinoma of the Thyroid Gland". The Oncologist. 16 (5): 585–593. doi:10.1634/theoncologist.2010-0405. ISSN 1083-7159.